Get the Daily Brief
Latest Biotech News
Regulatory and Industry Movements in Healthcare and Biotech
Recent regulatory actions and industry developments include the FDA maintaining a broad definition of cybersecurity devices in its latest guidance and Hong Kong establishing the Centre for Medical...
Psychedelic drug phase 2 success spurs Atai and Beckley merger plans
Atai Life Sciences and Beckley Psytech revealed positive Phase 2b results for intranasal mebufotenin in treatment-resistant depression, significantly reducing symptoms compared to low-dose...
AbbVie to acquire Capstan Therapeutics for $2.1 billion, boosting in vivo CAR-T pipeline
AbbVie secured a $2.1 billion acquisition of Capstan Therapeutics, gaining access to its early-phase in vivo CAR-T platform targeting autoimmune and cancer indications. The purchase follows...
Moderna’s mRNA flu vaccine beats approved comparator, sets up FDA submission
Moderna announced that its mRNA-based seasonal influenza vaccine, mRNA-1010, demonstrated a 26.6% relative vaccine efficacy over a licensed standard-dose flu vaccine in adults aged 50 and older...
CRISPR technology advances with web tools and new activation methods
Recent developments in CRISPR genome editing include novel web-based tools that improve off-target prediction by integrating individual genetic variations, enhancing precision in gene editing...
Pharmacogenomics trial in Scotland tests utility across 60 medications
A pharmacogenomics trial initiated in Scotland is recruiting up to 4,000 patients to evaluate the clinical utility of preemptive genetic testing across 60 medications. The study, conducted in...
AI and digital pathology collaborations expand precision medicine capabilities
Imagene AI closed a $23 million Series B financing round led by Oracle CTO Larry Ellison to advance multi-modal digital pathology foundation models that integrate histopathology, molecular...
Gut microbiota bioaccumulate toxic PFAS chemicals impacting human health
Groundbreaking research demonstrates that human gut bacteria can bioaccumulate per- and polyfluoroalkyl substances (PFAS), known as 'forever chemicals,' posing environmental and health concerns....
Clinical innovations in cancer and immunotherapy trials progress
Multiple clinical updates reflect ongoing advances in oncology, including Blacksmith Medicines securing a patent for antibacterial compounds targeting LpxC, Hemispherian receiving orphan drug...
Investment and M&A activity highlight biopharma market dynamics
Recent financial developments include Concentra Biosciences acquiring struggling biotech IGM Biosciences as part of an ongoing buyout streak and Innovent Biologics raising HKD 4.3 billion ($547...
U.S. Uterine Cancer Burden Set to Surge with Racial Disparities
Recent comprehensive studies led by Columbia University and published in major journals forecast a significant rise in uterine cancer incidence and mortality in the United States over the next 25...
Concentra Biosciences Accelerates M&A with Latest IGM Buyout
Concentra Biosciences, under hedge fund Tang Capital, has continued its aggressive acquisition strategy, picking up struggling biotech IGM Biosciences for $1.25 per share. This marks Concentra's...
Tempus AI Boosts Convertible Note Offering to $650 Million
Tempus AI increased its convertible senior notes offering from $400 million to $650 million to manage debt and reduce interest expenses. The Chicago-based precision medicine company offered notes...
Imagene AI Raises $23 Million Series B for Digital Pathology Models
Imagene AI, a Miami-based firm developing AI-enabled digital pathology tools, secured $23 million in a Series B financing round led by Oracle's Larry Ellison. The company uses advanced foundation...
Moderna’s mRNA Flu Vaccine Outperforms Competitors in Phase 3 Trial
Moderna announced top-line results from its Phase 3 trial of the mRNA-1010 seasonal influenza vaccine, showing a 26.6% relative vaccine efficacy compared to a licensed standard-dose shot in adults...
AbbVie Acquires Capstan Therapeutics to Expand In Vivo CAR-T Portfolio
AbbVie announced the acquisition of Capstan Therapeutics for up to $2.1 billion, gaining access to Capstan’s in vivo CAR-T platform and its phase 1 autoimmune program targeting CD19. Capstan’s...
Novel Insights into Chemotherapy-Induced Genetic Damage Uncovered
Cutting-edge genomic studies from the Wellcome Sanger Institute, University of Cambridge, and Cambridge University Hospitals reveal distinct mutational signatures caused by various chemotherapy...
Breaking Ground in Psychedelic Therapy for Treatment-Resistant Depression
Beckley Psytech and Atai Life Sciences have reported promising results from mid-stage clinical trials of psychedelic-based treatments targeting treatment-resistant depression. Beckley's intranasal...
AI and Genomics Drive Breakthroughs Across Biotech Sector
The biotech sector is seeing rapid innovation at the intersection of artificial intelligence (AI) and genomics. Advances include AI-powered molecular diagnostics, computational drug discovery, and...
Psychedelic Therapy Advances in Treatment-Resistant Depression
Beckley Psytech has reported positive Phase 2b clinical trial results for its intranasal psychedelic compound BPL-003 in patients with treatment-resistant depression. The trial demonstrated...